依达拉奉防治进展性脑梗死的临床研究

目的:观察依达拉奉防治进展性脑梗死的治疗作用及安全性.方法:将160例脑梗死患者随机分成2组:依达拉奉组80例,常规治疗基础上加用依达拉奉治疗,依达拉奉 30 mg 稀释后 30 min 内静滴完,1次/12 h,连续 7 d;对照组80例,采用常规治疗.研究开始 7 d 后,观察脑梗死进展率、神经功能缺损评分、梗死灶体积变化及不良反应.结果:7 d 后脑梗死进展率试验组较对照组明显减少;且试验组神经功能缺损评分升高,梗死灶体积缩小,组间差异具有显著性.结论:早期应用依达拉奉治疗可以阻止脑梗死的进展,促进患者神经功能恢复,降低伤残率,改善预后,且副作用少,安全可靠.

Clinical efficacy of edaravone on progressive ischemic stroke

Objective:To evaluate the curative effect and the safety of edaravone on progressive ischemic stroke. Methods: 160 patients suffered with progressive ischemic stroke were randomly divided into experiment group and control group: 80 patients in experiment group were treated with edaravone 30 mg edaravone was diluted and intravenous infusion to each patient in 30 min, once every 12 hours, plus conventional therapy and each patients in this group were treated for seven days. The other 80 patients in control group accepted conventional therapy. After the treatment, the stroke progress degree, score of neurologic impairment, infarction focus and adverse effect were observed. Results: The stroke progress degree at seventh day in experiment group decreased obviously than that in control group; furthermore, the neurological function score was improved and infarction focus bulk grow downwards; there were significant difference between the two groups. Conclusion: Early treatment with edaravone can delay the development of progressive ischemic stroke, degrade the disability and improve the prognosis; at the same time, the adverse effect of edaravone is very few.